INSIGHTS ON CLINICAL TRIAL TECHNOLOGIES

• The Role Of Technology In Improving Site Performance

  Explore how clinical trial sponsors can benefit from the growing use of electronic source (eSource) technology at research sites.

• Choosing The Right Platform: A Comparison For Regulated Industries

  Regulated industries depend on tightly controlled review workflows, yet common tools rarely meet those demands. Explore how purpose‑built solutions strengthen compliance and help streamline timelines.

• Setting A New Client Standard In Study Closeout Timelines

  Learn how a top-10 global pharmaceutical company achieved a significantly faster time to market for a high-profile therapy.

• Cytokine Release Syndrome Monitoring

  Here we introduce an innovative risk-monitoring solution aimed at mitigating Cytokine Release Syndrome (CRS), a critical complication in immunotherapy that often leads to prolonged hospitalization.

• Clinical Trial Technology Built For Confidence And Clarity

  10/6/2025

  Seamlessly integrate IRT, eCOA, patient and site payments, and travel management, with this patented technology that connects all the moving parts of a trial into one intelligent system.

• The Strategic Advantage Of eCOA And IRT

  8/11/2025

  The future lies in unified, interoperable eCOA–IRT solutions that streamline operations, improve data integrity, and enhance patient and site experience.

• How Strategic LQPPV Outsourcing Future-Proofs PV Compliance In The AI Era

  8/8/2025

  As health authorities seek standardization across global processes and strong AI governance, working with an experienced PV partner will help minimize the burden of oversight and ensure compliance.

• Revolutionizing CRO Financial Management With Better Technology

  6/19/2024

  For contract research organizations (CROs), the reliance on Excel is giving way to specialized technology, marking a pivotal shift in financial management strategies.

• A Framework For Selecting Reliable Clinical Endpoints From Real-World DHT Data

  2/25/2025

  Dr. Andy Liu presents a case study determining which digital measure of physical activity would be a well-defined and reliable clinical endpoint in a trial including patients with diabetes.